Drug intelligence / Profile preview

PF-07225570

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravesical[2]

Overview

PF-07225570 is an investigational small molecule antineoplastic drug developed by Pfizer for the treatment of recurrent non-muscle invasive bladder cancer. Its precise mechanism of action has not been publicly defined. The drug was evaluated as a monotherapy and in combination with an anti-PD-1 antibody in early-phase clinical trials targeting patients with intermediate or high-risk recurrent non-muscle invasive urothelial carcinoma who are ineligible for or have declined radical cystectomy. Development reached Phase 1 clinical trials but was subsequently discontinued[2][3][5][7].

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on PF-07225570.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07225570.

Explore the full profile